Litcius/Paper detail

143P Efficacy and safety of the anti-PD-L1 monoclonal antibody Socazolimab in combination with carboplatin and etoposide for extensive-stage small cell lung cancer: Results from the phase Ib clinical trial

Sheng Lu, Z. Chen, Zhouxiao Li, Zhuochao Zhou, Y. Yu, Xinghao Ai, Yizhou Zhao, Xiaoyin Niu, Jianli Cui, Renhua Guo, Bolong Li, Xiangrong Dai, Y. Li, Michael Wong, Rachel Ng, Zewei Zhao

2022Annals of Oncology12 citationsDOI

Topics & Concepts

MedicineCarboplatinTolerabilityEtoposideInternal medicineClinical endpointLung cancerAdverse effectPhases of clinical researchClinical trialSurgeryChemotherapyOncologyCisplatinLung Cancer Research StudiesPeptidase Inhibition and AnalysisLung Cancer Treatments and Mutations
143P Efficacy and safety of the anti-PD-L1 monoclonal antibody Socazolimab in combination with carboplatin and etoposide for extensive-stage small cell lung cancer: Results from the phase Ib clinical trial | Litcius